The field safety and efficacy of a bivalent Marek's disease (MD) vaccine (herpesvirus of turkeys + strain SB-1) administered in ovo were evaluated. The vaccine was administered to commercial broiler chicken eggs using Embrex's INOVOJECT automated egg-injection system. Comparisons were made with a conventional method of vaccination, in which the vaccine was administered subcutaneously to chicks at hatching. In ovo administration of the vaccine at day 17.5-18.5 of incubation significantly reduced the number of culled chicks, early mortality, and overall mortality during the grow-out period compared with conventional vaccination. However, hatchability was significantly lower in in ovo-treated chicks. Overall livability and feed efficiency were higher in the in ovo-treated chicks than in conventionally vaccinated chicks. Total field-caused condemnations and condemnations due to airsacculitis and septicemia/toxemia were also lower in the in ovo-vaccinated chicks. No difference in the leukosis (MD) condemnation rate was observed between the two treatment groups. In ovo vaccination provided 93.25% protection against challenge with a very virulent strain of MD virus (strain RB1/B); by comparison, the conventional vaccination method provided 89.58% protection.

Background and Aim: Infection of commercial poultry with avian encephalomyelitis (AE) and fowlpox (FP) virus causes heavy economic loss in endemic areas. Although vaccines are routinely used to control these two diseases, the problem still persists almost all over the world. This study aimed to evaluate safety and efficacy of a unique AE + FP + pigeon pox (PP) live virus vaccine in layer-type chickens under both laboratory and field conditions. Materials and Methods: The study was conducted using 289 specific-pathogen-free (SPF) chickens under the laboratory conditions and 185,648 commercial layer-type chickens under field conditions. In two consecutive laboratory trials, 8-week-old SPF chickens were vaccinated with the AE + FP + PP live virus vaccine through wing web route and challenged against virulent strains of FP and AE viruses at 3-week post-vaccination (WPV). Challenged chickens were observed for disease protection for 10-21 days. For field safety trials, commercial layer-type chickens in three different geographical areas in the USA were vaccinated with the AE + FP + PP vaccine and observed daily up to 21 days for vaccine "take". adverse reactions, and mortality. Results: The vaccine was found safe and efficacious under both laboratory and field conditions. Vaccine "take" and protection against FP challenge were 100%. Average protection against AE challenge was 97%. Mean AE enzyme-linked immunosorbent assay (ELISA) antibody titer in the field vaccinated chickens was >1200 at 10 WPV. Average daily post-vaccination mortality in the field vaccinated chickens was 0.04%. So far, more than 400 million chickens in the USA have been vaccinated with this vaccine. No vaccine-associated adverse reactions, other safety issues, or immunity breakdown cases in the vaccinated flocks due to field virus infection have been reported. Conclusion: This unique vaccine containing AE, FP, and PP viruses in a single preparation was found to be safe and efficacious in controlling the diseases caused by the virulent field strains of AE and FP. Besides being safe and efficacious, this vaccine also offered distinct advantages over the traditional vaccination practices in controlling these two diseases in poultry. Keywords: avian encephalomyelitis, efficacy, field safety, fowlpox, live virus vaccine, pigeon pox, protection.

In high-challenge areas, 1-day-old chicks are often vaccinated with fowlpox vaccine to provide early protection against the disease. However, we were unable to find any information in the published literature on the safety and efficacy of live fowlpox virus vaccine in 1-day-old turkeys. In this study, we evaluated a freeze-dried chicken-embryo-origin live fowlpox virus vaccine for its safety and efficacy in 1-day-old turkey poults by administering the vaccine subcutaneously in the upper back of the neck. Following vaccination, the turkeys were observed for 3 wk for vaccine-associated mortality and adverse reactions. Efficacy was evaluated by challenging the turkeys against a standard challenge strain of fowlpox virus. The results of this study indicated that the vaccine was safe and efficacious for subcutaneous administration in 1-day-old turkeys. None of the vaccinated turkeys revealed any adverse reactions or mortality associated with the vaccine. The vaccine protected more than 98% of the turkeys against fowlpox virus challenge.

No abstract

No abstract